Seeking Alpha
23 Jul 2026, 06:15 UTC · 10w ago
Impact · against what's priced in
CNTB faces a binary catalyst with upcoming trial readouts for rademikibart, while the potential for a similar MoA to Dupixent introduces a long-term competitive risk for SNY and REGN. The immediate impact is concentrated on CNTB's volatility risk around the Seabreeze STAT data.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
CNTB is approaching clinical readouts for two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, regarding rademikibart's efficacy for acute exacerbations.
More positive than 93% of claims this week
Rademikibart utilizes a similar mechanism of action to the blockbuster drug Dupixent (SNY/REGN).
Continue reading
5 related stories
Approaching clinical readouts for the Seabreeze STAT Asthma and COPD trials creates a significant near-term catalyst for the stock.
Read from the article alone
No priced-in read yet
The development of rademikibart with a similar mechanism of action to Dupixent introduces a potential future competitor in the respiratory space.
Read from the article alone
No priced-in read yet
The emergence of a similar MoA drug from CNTB poses a long-term competitive threat to the Dupixent franchise.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 65% of claims this week
CNTB ended Q1'26 with $46M in cash after raising $18.6M via a private placement.
So whatProvides a baseline for the company's runway, reducing immediate bankruptcy risk but remaining a secondary concern compared to trial data.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company is approaching key trial readouts and successfully raised capital via private placement.
More negative than 64% of ticker scores this week
CNTB is developing a drug with a similar mechanism of action to their blockbuster product, potentially creating future competition.
More negative than 64% of ticker scores this week
CNTB is developing a drug with a similar mechanism of action to their blockbuster product, potentially creating future competition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
TechCrunch
21h ago
More positive than 34% of relationship scores this week
[mutual] CNTB is developing a drug with a similar mechanism of action to Regeneron's Dupixent.
—
No price for SNE right now — the quote feed didn't answer.
SNE chart →−57.9%
Price is moving against the score
$0.9270 vs $2.20 close before publication (Jul 22) · not market-adjusted
CNTB chart →+12.9%
Price is moving against the score
$735.20 vs $651.18 close before publication (Jul 22) · not market-adjusted
REGN chart →
